Khalili Mohammad, Soltani Madjid, Moghadam Shirin Amiri, Dehghan Parvin, Azimi Amirreza, Abbaszadeh Omid
Ph.D. of Nutrition, Assistant Professor, Neuroscience Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
M.D., Royan Stem Cell Technology, Tehran, Iran.
Electron Physician. 2017 Jul 25;9(7):4899-4905. doi: 10.19082/4899. eCollection 2017 Jul.
Multiple Sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system. Oxidative stress plays a major role in the onset and progression of MS. Asymmetric dimethylarginine (ADMA) formation is dependent on oxidative stress status.
We examined whether alpha-lipoic acid (ALA) as a potent antioxidant could improve the Expanded Disability Status Scale (EDSS) and decrease plasma level of ADMA in multiple sclerosis patients.
In a randomized, double-blinded clinical trial conducted at Sina Hospital in Tehran, Iran, from September 2009 to July 2011, 24 patients with relapsing-remitting MS were divided into a treatment group receiving ALA (1200mg/day) for 12 weeks and a control group receiving placebo. Then patients' EDSS and Plasma levels of ADMA were measured at baseline and 12 weeks later. Statistical analysis was done by SPSS software version 16 using the K-S test, Chi square, Mann-Whitney U-test and Wilcoxon test.
The plasma levels of ADMA in the intervention group were decreased significantly (p=0.04). Also, no patient had increased EDSS score in the supplement group, where 2 out of 12 patients in the placebo group experienced so. Comparing the serum level of ADMA between the two groups failed to show any significant change in the supplement group compared with the control group.
Considering that ADMA is produced by oxidative stress in MS patients and leads to increase of inflammation, ALA may have the potential of beneficial effects in them, in part, by decreasing the plasma level of ADMA and stopping progression.
The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: No. IRCT138812222602N2.
The authors received no financial support for the research, authorship, and/or publication of this article.
多发性硬化症（MS）是一种中枢神经系统的炎症性脱髓鞘疾病。氧化应激在MS的发病和进展中起主要作用。不对称二甲基精氨酸（ADMA）的形成取决于氧化应激状态。
我们研究了作为一种强效抗氧化剂的α-硫辛酸（ALA）是否能改善多发性硬化症患者的扩展残疾状态量表（EDSS）并降低血浆ADMA水平。
在2009年9月至2011年7月于伊朗德黑兰的西娜医院进行的一项随机双盲临床试验中，24例复发缓解型MS患者被分为接受ALA（1200mg/天）治疗12周的治疗组和接受安慰剂的对照组。然后在基线和12周后测量患者的EDSS和血浆ADMA水平。使用SPSS软件16版通过K-S检验、卡方检验、曼-惠特尼U检验和威尔科克森检验进行统计分析。
干预组的血浆ADMA水平显著降低（p = 0.04）。此外，补充剂组中没有患者的EDSS评分增加，而安慰剂组的12名患者中有2名出现了这种情况。两组之间ADMA血清水平的比较未显示补充剂组与对照组相比有任何显著变化。
鉴于MS患者中ADMA由氧化应激产生并导致炎症增加，ALA可能对他们有潜在的有益作用，部分原因是通过降低血浆ADMA水平并阻止病情进展。
该试验在伊朗临床试验注册中心（http://www.irct.ir）注册，注册号：No. IRCT138812222602N2。
作者未获得该研究、撰写和/或发表本文的资金支持。
